Home Tools
Log in
Cart

c-RET

RET is the receptor for GDNF-family ligands (GFLs).
Cat. No. Product name CAS No. Purity Chemical Structure
T14928 Agerafenib hydrochloride 1227678-26-3 98%
Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM).
T67779 Compound TPX-0046 2411115-73-4 98%
Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.
T20742 TG-89 936091-56-4 98%
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cer...
T10823 Trans-Pralsetinib 2097132-93-7 98%
trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET) extracted from patent US20170121312A1 (Compound Example 129).
T16995 TAS05567 1429038-15-2 98%
TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...
T35384 TPX-0046 2359650-19-2 98%
TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.
T8402 Regorafenib Hydrochloride 835621-07-3 100%
Regorafenib Hydrochloride is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor ac...
TQ0059 Ilorasertib 1227939-82-3 96.17%
Ilorasertib (ABT-348) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora A/Aurora B/Aurora C (IC50s: 120 nM/7 nM/1 nM). It also suppress...
T7418 BBT594 882405-89-2 96.56%
BBT594(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.
T2032 WHI-P180 211555-08-7 97.74%
WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
TQ0277 Pralsetinib 2097132-94-8 97.88%
Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RE...
T2358 ENMD-2076 934353-76-1 98%
ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.
T10157 Regorafénib N-oxyde (M2) 835621-11-9 98.03%
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1 (IC50s: 13/4.2...
T22349 JNJ-38158471 951151-97-6 98.04%
CS-2660, a highly selective, orally available, well tolerated VEGFR2 inhibitor with IC50 of 40 nM, inhibits closely related tyrosine kinases such as Ret and Kit ...
T6028 PF 477736 952021-60-2 98.34%
PF-477736 is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.
T10624 BT-13 924537-98-4 98.41%
BT-13 is a selective agonist of glial cell line-derived neurotrophic factor (GDNF) receptor RET independently of GFLs. BT-13 promotes neurite growth from sensory...
T2094 Danusertib 827318-97-8 98.44%
Danusertib is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may ...
T2282 RPI-1 269730-03-2 98.91%
RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
T3065 TG101209 936091-14-4 99%
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.
T2070 Agerafenib 1188910-76-0 99.23%
CEP-32496 is a highly potent inhibitor of BRAF.
Agerafenib hydrochloride
T14928
Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM).
Compound TPX-0046
T67779
Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.
TG-89
T20742
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cer...
trans-Pralsetinib
T10823
trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET) extracted from patent US20170121312A1 (Compound Example 129).
TAS05567
T16995
TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...
TPX-0046
T35384
TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.
Regorafenib Hydrochloride
T8402
Regorafenib Hydrochloride is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor ac...
Ilorasertib
TQ0059
Ilorasertib (ABT-348) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora A/Aurora B/Aurora C (IC50s: 120 nM/7 nM/1 nM). It also suppress...
BBT594
T7418
BBT594(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.
WHI-P180
T2032
WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
Pralsetinib
TQ0277
Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RE...
ENMD-2076
T2358
ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.
Regorafénib N-oxyde (M2)
T10157
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1 (IC50s: 13/4.2...
JNJ-38158471
T22349
CS-2660, a highly selective, orally available, well tolerated VEGFR2 inhibitor with IC50 of 40 nM, inhibits closely related tyrosine kinases such as Ret and Kit ...
PF 477736
T6028
PF-477736 is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.
BT-13
T10624
BT-13 is a selective agonist of glial cell line-derived neurotrophic factor (GDNF) receptor RET independently of GFLs. BT-13 promotes neurite growth from sensory...
Danusertib
T2094
Danusertib is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may ...
RPI-1
T2282
RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
TG101209
T3065
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.
Agerafenib
T2070
CEP-32496 is a highly potent inhibitor of BRAF.
1 2